Geneva, 27 June 2024 – Following the voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare in late 2020, there has been notable progress in Azerbaijan, Belarus, and Kazakhstan regarding the transition to dolutegravir (DTG)-based treatments for HIV. By June 2024, the concerted efforts of various stakeholders have led to significant price reductions and the procurement of treatment volumes that promise to cover a substantial percentage of individuals on antiretroviral treatment (ART).
In Belarus and Kazakhstan, the national HIV programs have successfully procured enough DTG-based regimens to cover 78% and 86% of people on ART, respectively. Azerbaijan is on track to reach 65% of people on ART with DTG-based regimens this year. These achievements were made possible by price reductions of over 90%, reflecting the extensive work of communities, civil society, governments, procurement agencies, funders, clinicians and many others.
This MPP-ViiV licence includes four upper-middle-income countries, with Malaysia also benefiting from the agreement. The Ministry of Health of Malaysia is committed to provide people living with HIV with DTG regimens and planning to accelerate the transition to TLD starting from 2025.
This update demonstrates the impact of the continuous efforts and developments in increasing access to DTG-based treatments in these countries. It reflects the commitment to improve healthcare outcomes for those affected by HIV.
Read the full press release here.
Source : Medicines Patent Pool
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.